�������ýҕ�l

HHS said it will no longer allocate doses of COVID-19 antibody drugs from Eli Lilly and Regeneron because they are no longer in short supply, according to the American Hospital Association. Healthcare providers should now order the drugs directly from AmerisourceBergen, the sole distributor of the antibody drugs. The drugs will still be free, HHS said, according to a Feb. 19 news release from the hospital association.  (Anderson, 2/23)

University Hospitals will serve as one of the first sites in the nation for a clinical trial evaluating an investigational drug for COVID-19 patients who don't need to be hospitalized, according to a news release. A novel, orally-administered serine protease inhibitor called RHB-107 has demonstrated antiviral and potential tissue-protective effects, according to the release. RedHill Biopharma is evaluating the study drug, also known as Upamostat, in a Phase 2/3 study for treating patients with symptomatic COVID-19 who don't require inpatient care. (Coutre, 2/23)

The mystery of what happened to critical evidence proving Theranos’ blood-testing technology didn’t work deepened when Elizabeth Holmes blamed the government for what she calls an “investigative failure. ”In a filing late Tuesday, attorneys for Holmes shot back at prosecutors on a motion to exclude evidence of so-called test results, saying they are at fault for losing a database called the Laboratory Information System (LIS),  which contained three years worth of accuracy and failure rates of Theranos tests. (Khorram, 2/23)

In early May, a wing of Ohio State University’s Wexner Medical Center was eerily empty. The space had been cleared of patients as the pandemic raged. But it wasn’t going to waste. (Palmer, 2/24)